Suzuki Makoto, Seki Atsushi, Takamisawa Itaru, Tobaru Tetsuya, Takayama Morimasa, Sumiyoshi Tetsuya, Tomoike Hitonobu
Department of Cardiovascular Medicine, Sakakibara Heart Institute, Tokyo, Japan.
Int J Cardiol Heart Vasc. 2015 Jun 17;8:108-113. doi: 10.1016/j.ijcha.2015.06.004. eCollection 2015 Sep 1.
We retrospectively investigated our hypothesis that pre-percutaneous coronary intervention (PCI) procedural therapeutic hypothermia may have clinical advantages in patients with a profound cardiogenic shock complicating anterior ST-segment elevation myocardial infarction (STEMI).
Of 483 consecutive patients treated with PCI for a first anterior STEMI including 31 patients with aborted sudden cardiac arrest between 2009 and 2013, a total of 37 consecutive patients with an anterior STEMI complicated with profound cardiogenic shock defined as the presence of hyperlactic acidemia (serum levels of lactate > 4 mmol/L) with mechanical circulatory support were identified. An impaired myocardial tissue-level reperfusion (angiographic myocardial blush grade 0 or 1) and in-hospital mortality were evaluated in accordance with the presence or absence of pre-PCI procedural therapeutic hypothermia.
Thirteen patients were treated with pre-PCI procedural therapeutic hypothermia and 24 were not inducted with therapeutic hypothermia. Five patients with and 18 without pre-PCI procedural therapeutic hypothermia impaired myocardial tissue-level reperfusion (38% vs. 75%, p = 0.037). A total of 26 patients with in-hospital death (overall in-hospital mortality 70%) were composed of 6 with and 20 without therapeutic hypothermia (in-hospital mortality 46% vs. 83%, p = 0.028). A multivariate analysis demonstrated a significant association of pre-PCI procedural therapeutic hypothermia (p = 0.021) with in-hospital survival benefit. Adverse events associated with therapeutic hypothermia were not found in 12 patients who completed this treatment.
The present study may imply a crucial possibility of clinical benefits of pre-PCI procedural therapeutic hypothermia in patients with a cardiogenic shock complicating anterior STEMI.
我们进行了一项回顾性研究,以验证我们的假设,即对于因前壁ST段抬高型心肌梗死(STEMI)并发严重心源性休克的患者,经皮冠状动脉介入治疗(PCI)前进行治疗性低温可能具有临床优势。
在2009年至2013年期间,对483例首次因前壁STEMI接受PCI治疗的连续患者进行研究,其中包括31例心脏骤停未遂患者。共确定了37例因前壁STEMI并发严重心源性休克的连续患者,严重心源性休克定义为存在高乳酸血症(血清乳酸水平>4 mmol/L)并接受机械循环支持。根据PCI术前是否进行治疗性低温,评估心肌组织水平再灌注受损情况(血管造影心肌 blush分级为0或1)和院内死亡率。
13例患者在PCI术前接受了治疗性低温,24例未接受治疗性低温。接受PCI术前治疗性低温的5例患者和未接受治疗性低温的18例患者存在心肌组织水平再灌注受损(38%对75%,p = 0.037)。共有26例患者在院内死亡(总体院内死亡率70%),其中6例接受了治疗性低温,20例未接受治疗性低温(院内死亡率46%对83%,p = 0.028)。多因素分析表明,PCI术前治疗性低温(p = 0.021)与院内生存获益显著相关。在完成该治疗的12例患者中未发现与治疗性低温相关的不良事件。
本研究可能提示,对于因前壁STEMI并发心源性休克的患者,PCI术前进行治疗性低温可能具有临床获益的关键可能性。